Explore: Ursodeoxycholic Acid

Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal

of ursodeoxycholic acid (UDCA). Humans have only trace amounts of tauroursodeoxycholic acid but bears have large amounts of tauroursodeoxycholic acid and

cancer, fecal concentrations of bile acids are higher, particularly deoxycholic acid. The effects of ursodeoxycholic acid in modifying the risk of colorectal

the treatment of ICP, current evidence suggests ursodeoxycholic acid (UDCA), a minor secondary bile acid in humans, is the most effective drug for reducing

concentration of certain naturally occurring bile acids, such as chenodeoxycholic acid and ursodeoxycholic acid. On an empty stomach – after repeated vomiting

lithocholic acid, and they metabolize cholic acid into deoxycholic acid. There are additional secondary bile acids, such as ursodeoxycholic acid. Deoxycholic

cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable

of bile is affected due to cystic fibrosis) a medication called ursodeoxycholic acid may be given. Model for end-stage liver disease (MELD) "Liver Diseases"

treatment for PBC is ursodeoxycholic acid (UDCA). UDCA has been the only drug available for two decades and more recently obeticholic acid (OCA), a semi-synthetic

researchers believe that it may still be useful to offer ursodeoxycholic acid to women whose bile acids are > 40 μmol/litre. While there is no cure for ICP